Emerging evidence indicates that interactions between bacteria shape the nasopharyngeal microbiome and influence respiratory health. This Review uses the systematic scoping methodology to summarise 88 studies including observational and experimental studies, identifying key interactions between bacteria that colonise the human nasopharynx. A range of bacterial interactions were reported in the observational studies, including a variable association between Streptococcus pneumoniae and Haemophilus influenzae, a consistent positive association between S pneumoniae and Moraxella catarrhalis, and a consistent negative association between S pneumoniae and Staphylococcus aureus. Experimental studies largely validated the associations reported in the observational studies and provided insights into the mechanism and direction of interactions. In the context of respiratory health, non-pneumococcal alpha-haemolytic streptococci and the Gram-positive commensals Dolosigranulum and Corynebacterium inhibited respiratory pathogens such as H influenzae, S pneumoniae, M catarrhalis, and S aureus. These findings underscore how bacterial competition and coexistence shape the microbiome composition in this niche. This study has relevance for respiratory health and can be helpful for informing the design of potential microbiota-targeted therapies.
Multidrug resistant (MDR) P. aeruginosa accounts for 35% of all P. aeruginosa isolated from respiratory samples of patients with cystic fibrosis (CF). The usefulness of β-lactam antibiotics for treating CF, such as carbapenems and later generation cephalosporins, is limited by the development of antibacterial resistance. A proven treatment approach is the combination of a β-lactam antibiotic with a β-lactamase inhibitor. New β-lactam/β-lactamase inhibitor combinations are available, but data are lacking regarding the susceptibility of MDR CF-associated P. aeruginosa (CFPA) to these new combination therapies. In this study we determined MIC values for three new combinations; imipenem-relebactam (I-R), ceftazidime-avibactam (CZA), and ceftolozane-tazobactam (C/T) against MDR CFPA (n = 20). The MIC90 of I-R, CZA, and C/T was 64/4, 32/4, and 16/8 (all µg/mL), respectively. The susceptibility of isolates to imipenem was not significantly improved with the addition of relebactam (p = 0.68). However, susceptibility to ceftazidime was significantly improved with the addition of avibactam (p < 0.01), and the susceptibility to C/T was improved compared to piperacillin/tazobactam (p < 0.05) These data provide in vitro evidence that I-R may not be any more effective than imipenem monotherapy against MDR CFPA. The pattern of susceptibility observed for CZA and C/T in the current study was similar to data previously reported for non-CF-associated MDR P. aeruginosa.
23 October 2021 in Letters in Applied Microbiology
Broth microdilution assays were used to determine minimum inhibitory concentrations (MICs) and fractional inhibitory concentration indices (FICIs) of tea tree oil (TTO), tobramycin, colistin, and aztreonam against clinical cystic fibrosis-associated P. aeruginosa (CFPA) isolates (n=20). The minimum biofilm eradication concentration (MBEC) and fractional biofilm eradication concentration index (FBECI) were also determined using a similar microbroth dilution checkerboard assay, with biofilms formed using the MBEC device®. TTO was effective at lower concentrations against multi-drug resistant (MDR) CFPA isolates (n=3) in a biofilm compared to in a planktonic state (MBEC 18.7-fold lower than MIC). CFPA within biofilm was less susceptible to aztreonam, colistin and tobramycin compared to planktonic cells (MBEC 6.3-fold, 9.3-fold, and 2.1-fold higher than MIC, respectively). All combinations of essential oil and antibiotic showed indifferent relationships (FICI 0.52 - 1.72) when tested against planktonic MDR CFPA isolates (n=5). Against CFPA isolates (n=3) in biofilm, combinations of TTO/aztreonam and TTO/colistin showed indifferent relationships (mean FBECI 0.85 and 0.60, respectively), whereas TTO/tobramycin showed a synergistic relationship (mean FBECI 0.42). The antibiofilm properties of TTO and the synergistic relationship seen between TTO and tobramycin against CFPA in vitro make inhaled TTO a promising candidate as a potential therapeutic agent.
18 July 2022 in Complementary Therapies in Clinical Practice
With the steady rise in antifungal resistance amongst clinically important yeasts, antifungal drug discovery remains of the utmost importance. To determine the potential of some honeys as alternative antifungal agents, we quantified the antifungal activity of 12 Western Australian honey samples, two Manuka honey samples and an artificial honey against 10 yeast isolates including clinical and reference strains. Results showed that the tested honeys varied in activity, and yeasts species also differed in susceptibility, with minimum inhibitory concentrations (MICs) determined by broth microdilution ranging from 8% to >44% w/v honey. Honeys with the highest overall activity were derived from Blackbutt (Eucalyptus patens), Jarrah (E. marginata), and Karri (E. diversicolor). The optical density of each MIC microtitre plate was determined after incubation and showed that at relatively low concentrations of honey the growth of all yeasts was enhanced compared to the untreated control, whereas at and above approximately 12% w/v, honeys exerted a dose‐dependent growth inhibitory effect, the extent of which varied by honey type. Time‐kill studies with 64% w/v honey showed that all eight of the natural honeys tested had greater fungicidal activity than the comparator artificial honey. Our findings suggest that the specific nectar‐derived phytochemicals present within each honey play an important role in antifungal activity, and support the notion that activity is due to a combination of factors including osmotic activity, hydrogen peroxide and phytochemical compounds. These data indicate that honey is worthy of further investigation as a potential therapeutic agent for superficial yeast infections.
31 March 2026 in International Journal of Systematic and Evolutionary Microbiology
Microbiology Society journals contain high-quality research papers and topical review articles. We are a not-for-profit publisher and we support and invest in the microbiology community, to the benefit of everyone. This supports our principal goal to develop, expand and strengthen the networks available to our members so that they can generate new knowledge about microbes and ensure that it is shared with other communities.